BRAINQ TECHNOLOGIES LTD

Their core work

BrainQ Technologies is an Israeli medical technology SME developing non-invasive neurorehabilitation devices that use brain-computer interface (BCI) technology to generate precisely calibrated, very low-intensity electromagnetic fields tuned to each patient's neural frequencies. Their core product targets motor recovery in patients who have suffered stroke or other neurological disorders, using AI to personalize treatment parameters and IoT architecture to enable remote monitoring and data collection. The company progressed from a proof-of-concept feasibility study in 2018 to a fully funded product development and clinical validation program by 2020, suggesting a mature, product-focused trajectory rather than pure research. Their approach sits at the intersection of neuroscience, AI, and medical device engineering.

What they specialise in

How they've shifted over time

BrainQ's H2020 trajectory follows the classic SME instrument arc: a Phase 1 feasibility study in 2018 established the core BCI-electromagnetic concept and business case, followed by a substantially larger Phase 2 grant in 2020 to develop and validate the full product. The shift from a €50K concept study to a €2.25M development program signals that the technology cleared feasibility validation and moved into engineering and clinical evidence generation. There is no keyword drift in the traditional sense — the core science remained consistent — but the framing evolved from describing the underlying mechanism (electromagnetic field, BCI) to describing the commercial product and clinical outcome (AI-based IoT device, motor recovery).

BrainQ is on a product commercialization path — their Phase 2 grant funds full device development, suggesting they are approaching regulatory submission and market entry, making them a candidate partner for clinical validation networks, hospital systems, or medtech distributors rather than early-stage research consortia.

How they like to work

BrainQ has coordinated both of their H2020 projects independently, with no recorded consortium partners — consistent with the SME instrument design, which funds single companies rather than multi-partner consortia. This means there is no history of collaborative project execution to evaluate, and working with them would likely mean engaging them as a technology provider or clinical partner rather than as an experienced consortium builder. For future Horizon Europe consortia, they would most naturally slot in as a specialized technology SME contributor bringing a proprietary neurorehabilitation device platform.

BrainQ has not built a European partner network through their H2020 participation — both grants were solo SME instrument awards with no recorded consortium partners. Their network, if any, likely exists through clinical trial sites, investors, and Israeli biotech channels rather than through EU research collaboration.

What sets them apart

BrainQ occupies a specific niche within neurorehabilitation: frequency-tuned electromagnetic stimulation guided by BCI signals, which differentiates them from generic TMS or TENS device makers. Their combination of AI personalization and IoT connectivity on top of a proprietary neural-frequency targeting mechanism gives them a defensible technical position if clinical evidence holds up. For consortium builders, they offer access to a proprietary, CE/FDA-track medical device platform in an underserved rehabilitation segment — rare among Israeli SMEs active in EU funding programs.

Highlights from their portfolio

• BQ System
  The largest grant (€2.25M under SME Phase 2) funds full development of an AI-powered IoT medical device for stroke motor recovery — a high-stakes, product-defining program that will determine the company's commercial trajectory.
• BQ-Technology
  The Phase 1 feasibility study that validated the BCI-electromagnetic concept and unlocked the Phase 2 award, demonstrating that the core technology survived EU-level scientific scrutiny.